Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3

Conditions

Melanoma 16Leukemia, Myelogenous, Chronic, BCR-ABL Positive 11Carcinoma, Renal Cell 6Kidney Neoplasms 4Leukemia, Myeloid, Chronic-Phase 3Carcinoma, Hepatocellular 3Unspecified Adult Solid Tumor, Protocol Specific 2Polycythemia Vera 2Ovarian Neoplasms 2Neoplasm Metastasis 2Lymphoma 2Leukemia 2Hepatitis B, Chronic 2Fallopian Tube Neoplasms 2Brain Neoplasms 2Uveal Melanoma 1Thrombocytosis 1Thrombocythemia, Essential 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Sezary Syndrome 1Recurrence 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Osteosarcoma 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Neurofibroma 1Neoplasms 1

Interventions

Cyclophosphamide 83Peripheral Blood Stem Cell Transplantation 76fludarabine phosphate 74Busulfan 60Cyclosporine 57Imatinib Mesylate 50Mycophenolic Acid 49Antilymphocyte Serum 48Tacrolimus 44Radiotherapy 44Filgrastim 43Methotrexate 39Whole-Body Irradiation 34Dasatinib 34Methylprednisolone 30Cord Blood Stem Cell Transplantation 26nilotinib 25Melphalan 24Cytarabine 23Interferon-alpha 22Etoposide 20sargramostim 19Flow Cytometry 13Therapeutics 11Cyclosporins 11Sirolimus 10Polymerase Chain Reaction 10bosutinib 9Thiotepa 9Hydroxyurea 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Leukemia, Myeloid, Chronic-Phase × peginterferon alfa-2b × Clear all
NCT01933906 2019-01-04

Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response

Arbeitsgemeinschaft medikamentoese Tumortherapie

Phase 1 Completed
12 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT00050531 2016-05-11

High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)

M.D. Anderson Cancer Center

Phase 3 Completed
94 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT00303290 2015-11-26

PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML

M.D. Anderson Cancer Center

Phase 1 Completed
76 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡